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CASE REPORT 
 
Autonomic failure, which may include orthostatic hypotension (OH), supine hypertension, bowel 
and bladder disturbances, impaired thermal regulation and sexual dysfunction, can be features of 
Parkinson’s disease (PD) and other α-synucleinopathies. All patients with pure autonomic failure 
(PAF), most with multiple system atrophy (MSA) and 18% with PD will develop symptomatic OH 
[1]. However, the extent of central and peripheral norepinephrine deficiency, parasympathetic 
nuclei degeneration, and arterial baroreflex failure may be differentially impaired in these disorders 
[2, 3]. As a result, clinical features and prognosis of autonomic dysfunction in α-synucleinopathies 
may be more complex than previously envisioned. 
 
A 68-year-old man was admitted to the emergency unit for syncope and chest pain associated with 
orthostatism. Over the prior 12 months he had reported three syncopal events, constipation, erectile 
dysfunction, and profuse sweating. Blood pressure (BP) was 148/98 mmHg, supine, and 80/50 
mmHg, upright.  Electrocardiography (ECG), 24h ECG monitoring, and coronary angiography were 
normal, while echocardiography revealed left ventricular hypertrophy. The autonomic evaluation 
showed nocturnal hypertension with a “reverse dipping” pattern on ambulatory BP monitoring; 
significant BP drop in the lying-to-standing test (53/28 mmHg at 3 minutes; normal < 20/10 mmHg 
[systolic/diastolic]); decreased heart rate variability (HRV) as measured by deep breathing test 
(Expiratory/Inspiratory ratio= 1.01; normal ≥ 1.1), lying-to-standing test (30:15 ratio= 1.0; normal ≥ 
1.04), and Valsalva maneuver (Valsalva Ratio= 1.04; normal ≥ 1.14); and markedly low 
catecholamine plasma levels in both supine and orthostatic positions (Figure 1). Brain magnetic 
resonance imaging, peripheral nerve conduction studies (bilateral evaluation of peroneal, tibial, 
ulnar, median, and sural nerves distal latencies, amplitudes, motor and/or sensory nerve conduction 
velocities), vestibular tests, carotid/vertebral Doppler ultrasonography and neurological examination 
were normal. A 123Metaiodobezilguanidyne (123MIBG) cardiac positron emission tomography 
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demonstrated widespread sympathetic denervation (Figure 1). He was managed with midodrine 15 
mg/day, and fludrocortisone 0.1 mg/day. Three years later, he developed resting tremor in the right 
hand and foot, associated with mild bradykinesia. Brain [123I] FP-CIT-SPECT (DAT-SCAN) 
showed abnormal radioligand binding affecting the left putamen. A diagnosis of PD was made and 
treatment with rasagiline (1 mg/day) started, lowering the Unified Parkinson’s Disease Rating Scale 
(UPDRS) part III from 11/108 to 6/108. The Scale for Outcome in Parkinson’s disease-Autonomic 
(SCOPA-AUT) and Non-Motor Symptom Scale (NMSS) scores were 30 and 50, respectively. 
Significant alterations were found in the cardiovascular, sexual function, gastrointestinal tract, and 
fatigue sub-items. Moreover, the patient reported excessive sweating, mild alterations of smell, and 
mild problems sustaining concentration. No alterations were reported in mood/cognition, perceptual 
problems/hallucinations, and urinary functions. Four years later, upon worsening of tremor and 
bradykinesia (UPDRS-III, 14/108); low-dose levodopa/carbidopa (50/12.5 t.i.d.) was administered 
for 2 weeks, followed by significant motor improvement (UPDRS-III, 7/108). However, OH 
worsened, with an increase of NMSS item 1 (lightheadedness when standing) frequency from 3 
(frequent) to 4 (Very frequent). In addition, presyncopal episodes associated with standing were 
reported 1-3 hours after each levodopa dose, with documented BP falls > 30/15 mmHg 
(systolic/diastolic).  
After more than 10 years from the onset of autonomic features, and 7 from motor features, 
dysautonomia with prominent OH remained a levodopa-limiting major source of disability with 
motor symptoms modestly improved with rasagiline 1 mg/day (UPDRS-III, 15/108). 
 
In this letter we report the long-term follow-up of a patient with severe autonomic dysfunction as 
presenting symptom of PD. The clinical features initially suggested MSA or PAF, but the abnormal 
123MIBG scan and the low orthostatic catecholamine plasma levels argued against a diagnosis of 
MSA, and the profuse sweating was atypical for PAF (Table 1). The early differential diagnosis of 
α-synucleinopathies is challenging given the different prognosis (10-year survival rate of 33% in 
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MSA, 87% in PAF, 74% in PD+OH, and 93% in PD without OH [3]) and the heterogeneous 
pathogenic mechanisms involved (Table 1). MSA is characterized by glial cytoplasmic inclusions 
of α-synuclein, with central catecholaminergic deficiency, degeneration of parasympathetic nuclei 
and preserved peripheral sympathetic innervation [4]. Conversely, PAF and PD are characterized by 
neuronal inclusions of α-synuclein deposited as cytoplasmic Lewy bodies, differing only in their 
distribution. PAF affects predominantly peripheral structures [4], while PD additionally involve 
central structures (Table 1), as suggested by the frequent association between OH, cognitive 
impairment and REM sleep behavioral disorder [5].  
 
The case reported in this letter highlights the clinical similarities between PD and PAF, raising the 
question of whether PAF represents a restricted Lewy body synucleinopathy or an early 
manifestation of PD, as proposed by Kaufmann and colleagues [6]. The possibility exists that 
certain biological processes, as yet unrecognized, may succeed in restricting Lewy body pathology 
to the peripheral autonomic nervous system (as lifelong PAF) or fail by allowing its slow spread 
into the central nervous system (as prodromal dysautonomia in PD). Understanding these biological 
processes may inform the development of future neuroprotective strategies in PD. 
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FIGURE CAPTIONS AND LEGENDS 
 
Fig. 1 
 
123MIBG SCAN, DAT-SCAN, AND PLASMA CATECHOLAMINE LEVELS  
a) 123MIBG scan demonstrated widespread cardiac sympathetic denervation; b) DAT-SCAN 
showed abnormal radioligand binding affecting the left putamen; c) catecholamine plasma 
concentrations showed low norepinephrine levels in both supine and standing positions  
 
 
 
